RA0056

antibody from Oursmab

Targeting: C5AR1 C5A, C5AR, C5R1, CD88

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0056

Provider

Oursmab

Product name

Avdoralimab (Biosimilar Reference Antibody) (C5AR1)

Antibody type

Monoclonal

Description

Avdoralimab is a clinical-stage, fully human monoclonal antibody designed as a selective antagonist of the complement C5a receptor 1 (C5aR1, also known as CD88). It functions by specifically binding to C5aR1 on the surface of myeloid cells, thereby blocking the interaction with its potent pro-inflammatory ligand, C5a. This blockade aims to inhibit C5a-mediated recruitment and activation of neutrophils and other immune cells in inflammatory tissues. It is currently being evaluated in Phase II clinical trials, primarily investigated in combination with other agents for the treatment of severe COVID-19 pneumonia (to counteract the complement-driven "cytokine storm") and for certain cancers (to modulate the immunosuppressive tumor microenvironment).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.